Related Experiment Video
Updated: Feb 10, 2026

Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
Antiplatelet Therapy, Cerebral Microbleeds, and Intracerebral Hemorrhage: A Meta-Analysis
Jianting Qiu1, Huirong Ye1, Jialiang Wang1
1From the Department of Neurology, Cerebrovascular Disease Center, People's Hospital, China Medical University, Shenyang, People's Republic of China.
Background And Purpose:
Antiplatelet therapy is associated with the presence of cerebral microbleeds (CMBs) with limited studies. We further investigate the topic focusing on different effects of antiplatelet therapy on strict lobar and deep/infratentorial MBs.
Methods:
We searched PubMed and EMBASE from January 1, 1997 to December 1, 2017, for relevant studies, calculated the pooled odds ratios (OR) for CMB incidence and distribution (strictly lobar, deep/infratentorial) in antiplatelet users versus nonantiplatelet users and calculated the OR for the incidence of intracerebral hemorrhage in antiplatelet users with CMBs versus those without.
Results:
We included 20 988 participants from 37 studies. CMBs were more frequent in antiplatelet users than those in nonantiplatelet users (pooled OR, 1.21; 95% confidence interval, 1.07-1.36; P=0.002). There was a significant association of antiplatelet therapy with strictly lobar MBs (OR, 1.45; 95% confidence interval, 1.15-1.84; P=0.002) rather than deep/infratentorial MBs (OR, 1.37; 95% confidence interval, 0.98-1.90; P=0.062). Intracerebral hemorrhage incidence was higher in participants with CMBs than those without CMBs (OR, 3.40; 95% confidence interval, 2.00-5.78; P=0.000) in antiplatelet users.
Conclusions:
Antiplatelet drug use was associated with increased risk of strictly lobar MBs and increased the intracerebral hemorrhage incidence in participants with CMBs.
Insights
Antiplatelet therapy increases the risk of strictly lobar cerebral microbleeds (CMBs). This therapy also elevates the incidence of intracerebral hemorrhage in patients with CMBs.
Area of Science:
- Neurology
- Cardiovascular Research
- Clinical Trials
Background:
- Cerebral microbleeds (CMBs) are small hemorrhages in the brain.
- The association between antiplatelet therapy and CMBs requires further investigation.
- Differentiating effects on lobar versus deep/infratentorial CMBs is crucial.
Purpose of the Study:
- To investigate the association between antiplatelet therapy and cerebral microbleeds (CMBs).
- To analyze the differential impact of antiplatelet agents on strictly lobar versus deep/infratentorial CMBs.
- To assess the risk of intracerebral hemorrhage in antiplatelet users with CMBs.
Main Methods:
- Systematic review and meta-analysis of studies from PubMed and EMBASE (1997-2017).
- Pooled odds ratios (OR) calculated for CMB incidence and distribution.
- OR calculated for intracerebral hemorrhage incidence in antiplatelet users with and without CMBs.
Main Results:
- Included 37 studies with 20,988 participants.
- CMBs were more frequent in antiplatelet users (OR, 1.21).
- Significant association between antiplatelet therapy and strictly lobar CMBs (OR, 1.45).
- Higher intracerebral hemorrhage incidence in antiplatelet users with CMBs (OR, 3.40).
Conclusions:
- Antiplatelet drug use is linked to an increased risk of strictly lobar CMBs.
- Antiplatelet therapy elevates intracerebral hemorrhage risk in individuals with CMBs.
Related Concept Videos
Directing Effect of Substituents: meta-Directing Groups
Gene Therapy
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Group Therapy
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
Cerebral Hemispheres

